Objectives: To describe fetal abnormalities associated with a nuchal translucency (NT)>95th percentile measured at first trimester screening and investigate which of these anomalies would be missed if cell free fetal DNA (cfDNA) replaced an early scan. Methods: This is a retrospective study including 1661 pregnancies from five academic hospitals in the Netherlands with a NT≥p95 measured between 01-01-2010 and 31-12-2015. All cases with unknown pregnancy outcome were excluded. Pre-and postnatal information, results of karyotyping, detailed ultrasound examination, post-mortem results and investigation by a clinical geneticist was retrospectively collected for all pregnancies with a NT≥p95. All cases were sorted into three categories: no abnormalities, abnormalities detectable by cfDNA (Trisomy 21, 18 en 13) and abnormalities not detectable by cfDNA. The last group included genetic syndromes, structural abnormalities and microscopic genetic aberrations detectable by micro arrays. Results: 1661 pregnancies were included in the study. Mean maternal age was 34±5.0 years. Of all fetuses, 889 (53.5%) showed no abnormalities, 422 (25.4%) were affected by Trisomy 21, 18 or 13 which would have been identified by cfDNA and 350 (21.1%) had abnormalities not detectable by cfDNA. Of the 350 reported abnormalities, 172 were structural, 63 were genetic syndromes and 115 microscopic genetic aberrations diagnosed by micro arrays. Cardiac defects were the most common structural abnormalities (n=66, 18.9%) followed by urogenital anomalies (n=21, 6%). Conclusions: An increased NT is a marker for a variety of disorders. Besides chromosomal anomalies, also detected by cfDNA (24%), other anomalies (20%) would be missed by this test, indicating that an early scan for structural anomalies (including an increased NT) should be maintained if the aim of prenatal screening is to detect early in pregnancy as many anomalies as possible.
